Immunohistochemistry Market to Surpass US$ 2,448.93 Mn by 2030 - Coherent Market Insights

Global Immunohistochemistry Market, by Product (Antibodies, Consumables, Equipment), by Application (In Vitro Diagnostic Application, Research Application, Other), by End User (Hospitals, Diagnostic Laboratories, Academic & Research Institutes, Others) by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,463.69 million in 2022 and expected to exhibit a CAGR of  6.6 % over the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.

Key players operating in market are focusing on receiving product launches from the regulatory authorities, which is expected to drive the market growth over the forecast period.

For instance, in March 2020, ELITechGroup, Inc. a manufacturer and distributor of in vitro diagnostic equipment introduced Aerospray Cytology Slide Stainer Cytocentrifuge in its staining technology portfolio. This new product automated preparation and staining of cytology specimens to facilitate cell examination.

Moreover, for instance, in August 2020, Biocare Medical LLC, an innovator in automated immunohistochemistry (IHC) instrumentation, announced the launch of TIGIT monoclonal antibody for immunohistochemical applications.

Global Immunohistochemistry Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 a pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 609,247,113 cases of coronavirus disease (COVID-19) were reported till September 12, 2022, across the globe.

Global supply chains have faced considerable obstacles as a result of the COVID-19 pandemic. The flow of raw supplies and finished items is still being slowed or even temporarily stopped by numerous national lockdowns, which is affecting the production process.

This also impacted the global immunohistochemistry (IHC) market slightly due to delays in the supply chain and raw material transportation.

However, according to the Nature journal, December 2020, Immunohistochemistry and in situ hybridization techniques that allow for the identification of SARS-CoV and SARS-CoV-2 viral products in formalin-fixed paraffin-embedded (FFPE) specimens would be extremely useful in the future. These various strategies for virus detection and control material synthesis can be applied to studies of coronavirus pathogenesis and therapeutic research in animal models.

Therefore, there was an impact on the supply of immunohistochemistry kits and reagents during COVID-19 pandemic; however, its application in COVID-19 research and diagnosis is expected to increase its demand ahead in the future.

Browse 53 Market Data Tables and 38 Figures spread through 154 Pages and in-depth TOC on “Immunohistochemistry Devices Market” - Global Forecast to 2030, by Product (Antibodies, Consumables, Equipment), by Application ( In Vitro Diagnostic Application, Research Application, Others), by End User (Hospitals, Diagnostic Laboratories, Academic & Research Institutes, Other) by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the global Immunohistochemistry Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/immunohistochemistry-market-4795

Key players operating in market are focusing on the adoption of inorganic growth strategies such as mergers, collaborations, partnerships, and acquisitions, in order to strengthen their position in the global market. For instance, in September 2021, PerkinElmer, a company focused on diagnostics, life science research, environmental and industrial testing, announced the acquisition of reagent and antibody manufacturer BioLegend for approximately US$ 5.25 billion. With this acquisition, the company expanded its life science business to provide innovative solutions.

Key Takeaways of the Global Immunohistochemistry Market:

• Global immunohistochemistry market is expected to exhibit a CAGR of 6.6% over the forecast period, owing to rising studies for checking the usability of IHC in forensic applications. For instance, according to a study published by The American Journal of Forensic Medicine and Pathology, in 2018, a study included 120 forensic autopsy samples of liver, lung, and brain tissues obtained for diagnostic purposes. An overall correlation between the postmortem interval and the IHC score for all tissue samples was found. Samples from decedents with a postmortem interval of 1 to 3 days showed positive staining with all antibodies, whereas samples from decedents with a longer postmortem interval showed decreased staining rates. The results suggest that IHC analysis can be successfully used for postmortem diagnosis in a range of autopsy samples showing lesser degrees of decomposition.
• Among product, antibodies segment is expected to account for the largest market share during the forecast period, owing to increasing product launches. For instance, in August 2020, Biocare Medical LLC, an innovator in automated immunohistochemistry (IHC) instrumentation, announced the launch of TIGIT monoclonal antibody for immunohistochemical applications. The company developed this new production collaboration with Bethyl Laboratories, a manufacturer of polyclonal antibody products.
• Key players operating in the global immunohistochemistry market include Merck, Rockland Immunochemicals, Inc., F. Hoffman-la Roche Ltd, Thermo Fisher Scientific, PerkinElmer, Inc., Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., Bio SB, Agilent Technologies, Inc., Abcam plc., Becton, Dickinson and Company, Miltenyi Biotec, Biocare Medical, LLC, Eagle Biosciences, Inc., Bio-Techne, Diagnostic Biosystems, Inc., and BioGenex